SJR 29: EpiPen: pricing.
- Session Year: 2015-2016
- House: Senate
- Latest Version Date: 2016-09-09
This measure would urge the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen, would urge the Congress of the United States to investigate the impact that Mylan NVs monopoly has had on price increases for EpiPen, and would urge the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.
This measure would urge the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen, would urge the Congress of the United States to investigate the impact that Mylan NVs monopoly has had on price increases for EpiPen, and would urge the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.
This measure would urge the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen, would urge the Congress of the United States to investigate the impact that Mylan NVs monopoly has had on price increases for EpiPen, and would urge the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.
WHEREAS, Millions benefit from lifesaving drugs and devices, including Americans with allergies that can be treated by epinephrine; and
WHEREAS, Last year, doctors wrote 3.6 million prescriptions for EpiPen, which stops allergic reactions by quickly and safely injecting epinephrine; and
WHEREAS, In 2007 Mylan NV purchased the rights to EpiPen and immediately began raising its price. In 2008 and 2009, Mylan raised the price by 5 percent, and at the end of 2009 it raised the price by another 19 percent. From 2010 to 2013, Mylan imposed a series of 10-percent price hikes. And from the fourth quarter of 2013 to the second quarter of 2016, Mylan raised EpiPen prices 15 percent every other quarter; and
WHEREAS, A pack of two EpiPen devices now has a list price of over $600, an increase of 548 percent since Mylan began selling the drug, according to Truven Health Analytics; and
WHEREAS, The formula of EpiPen did not change, and it is no more effective in protecting against allergic reactions in 2016 than it was in 2007; and
WHEREAS, During the same time, Mylan began an aggressive marketing and lobbying effort to increase demand for EpiPen, which included the passage of federal and state legislation. The United States Congress passed the School Access to Emergency Epinephrine Act in 2013 to provide an incentive to states to boost the stockpile of epinephrine at schools. A number of states, including California, passed laws requiring public schools to have epinephrine. In 2010, the United States Food and Drug Administration (FDA) changed its recommendations so that two EpiPen devices be sold in a package instead of one and that they be prescribed for at-risk patients, not just those with confirmed allergies; and
WHEREAS, The rising cost of EpiPen has implications for taxpayers. Over half of Californias children are insured through Medi-Cal, therefore the taxpayers are paying a large share of the cost of this medication; and
WHEREAS, Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor; and
WHEREAS, Patients who have to pay retail prices are being forced to buy EpiPen abroad, where it is cheaper, and are resorting to other devices that deliver epinephrine, including do-it-yourself syringes; and
WHEREAS, Even some ambulance providers in California have stopped the use of EpiPen to treat allergic shock and instead are drawing from a vial and injecting epinephrine by syringe. First responders in Seattle have developed such a kit and have sold them to public health agencies in five other states. There is a demonstration project in New York called Check and Inject New York that trains first responders to use syringe epinephrine kits in place of EpiPen to save money; and
WHEREAS, After recent widespread criticism, Mylan said it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers and employers pay. Those institutions will still face the brunt of the impact from the price hikes; and
WHEREAS, Offering copayment assistance and free product to consumers is part of the standard playbook for manufacturers of expensive drugs. Efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medications ignores the fact that insurance companies bear the brunt of these unreasonable price increases, which results in higher premiums for all consumers; now, therefore, be it
Resolved by the Senate and the Assembly of the State of California, jointly, That the Legislature declares unnecessary and unexplained increases in pharmaceutical pricing is a harm to our health care system that will no longer be tolerated because the system cannot sustain it; and be it further
Resolved, That the Legislature urges the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to EpiPen; and be it further
Resolved, That the Legislature urges the Congress of the United States to investigate the impact that Mylans monopoly has had on the price hikes for EpiPen; and be it further
Resolved, That the Legislature urges the Congress and President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based only on what the market can bear rather than on providing a fair return on investment; and be it further
Resolved, That the Secretary of the Senate transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Majority Leader of the Senate, to each Senator and Representative from California in the Congress of the United States, to the Secretary of the United States Department of Health and Human Services, and to the Commissioner of Food and Drugs, and to the author for appropriate distribution.
WHEREAS, Millions benefit from lifesaving drugs and devices, including Americans with allergies that can be treated by epinephrine; and
WHEREAS, Last year, doctors wrote 3.6 million prescriptions for EpiPen, which stops allergic reactions by quickly and safely injecting epinephrine; and
WHEREAS, In 2007 Mylan NV purchased the rights to EpiPen and immediately began raising its price. In 2008 and 2009, Mylan raised the price by 5 percent, and at the end of 2009 it raised the price by another 19 percent. From 2010 to 2013, Mylan imposed a series of 10-percent price hikes. And from the fourth quarter of 2013 to the second quarter of 2016, Mylan raised EpiPen prices 15 percent every other quarter; and
WHEREAS, A pack of two EpiPen devices now has a list price of over $600, an increase of 548 percent since Mylan began selling the drug, according to Truven Health Analytics; and
WHEREAS, The formula of EpiPen did not change, and it is no more effective in protecting against allergic reactions in 2016 than it was in 2007; and
WHEREAS, During the same time, Mylan began an aggressive marketing and lobbying effort to increase demand for EpiPen, which included the passage of federal and state legislation. The United States Congress passed the School Access to Emergency Epinephrine Act in 2013 to provide an incentive to states to boost the stockpile of epinephrine at schools. A number of states, including California, passed laws requiring public schools to have epinephrine. In 2010, the United States Food and Drug Administration (FDA) changed its recommendations so that two EpiPen devices be sold in a package instead of one and that they be prescribed for at-risk patients, not just those with confirmed allergies; and
WHEREAS, The rising cost of EpiPen has implications for taxpayers. Over half of Californias children are insured through Medi-Cal, therefore the taxpayers are paying a large share of the cost of this medication; and
WHEREAS, Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor; and
WHEREAS, Patients who have to pay retail prices are being forced to buy EpiPen abroad, where it is cheaper, and are resorting to other devices that deliver epinephrine, including do-it-yourself syringes; and
WHEREAS, Even some ambulance providers in California have stopped the use of EpiPen to treat allergic shock and instead are drawing from a vial and injecting epinephrine by syringe. First responders in Seattle have developed such a kit and have sold them to public health agencies in five other states. There is a demonstration project in New York called Check and Inject New York that trains first responders to use syringe epinephrine kits in place of EpiPen to save money; and
WHEREAS, After recent widespread criticism, Mylan said it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers and employers pay. Those institutions will still face the brunt of the impact from the price hikes; and
WHEREAS, Offering copayment assistance and free product to consumers is part of the standard playbook for manufacturers of expensive drugs. Efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medications ignores the fact that insurance companies bear the brunt of these unreasonable price increases, which results in higher premiums for all consumers; now, therefore, be it
Resolved by the Senate and the Assembly of the State of California, jointly, That the Legislature declares unnecessary and unexplained increases in pharmaceutical pricing is a harm to our health care system that will no longer be tolerated because the system cannot sustain it; and be it further
Resolved, That the Legislature urges the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to EpiPen; and be it further
Resolved, That the Legislature urges the Congress of the United States to investigate the impact that Mylans monopoly has had on the price hikes for EpiPen; and be it further
Resolved, That the Legislature urges the Congress and President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based only on what the market can bear rather than on providing a fair return on investment; and be it further
Resolved, That the Secretary of the Senate transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Majority Leader of the Senate, to each Senator and Representative from California in the Congress of the United States, to the Secretary of the United States Department of Health and Human Services, and to the Commissioner of Food and Drugs, and to the author for appropriate distribution.
WHEREAS, Millions benefit from life-saving drugs and devices, including Americans with allergies that can be treated by epinephrine; and
WHEREAS, Last year, doctors wrote 3.6 million prescriptions for EpiPen, which stops allergic reactions by quickly and safely injecting epinephrine; and
WHEREAS, In 2007 Mylan NV purchased the rights to EpiPen and immediately began raising its price. In 2008 and 2009, Mylan raised the price by 5 percent, and at the end of 2009 it raised the price by another 19 percent. From 2010 to 2013, Mylan imposed a series of 10-percent price hikes. And from the fourth quarter of 2013 to the second quarter of 2016, Mylan raised EpiPen prices 15 percent every other quarter; and
WHEREAS, A pack of two EpiPen devices now has a list price of over $600, an increase of 548 percent since Mylan began selling the drug, according to Truven Health Analytics; and
WHEREAS, The formula of EpiPen did not change, and it is no more effective in protecting against allergic reactions in 2016 than it was in 2007; and
WHEREAS, During the same time, Mylan began an aggressive marketing and lobbying effort to increase demand for EpiPen, which included the passage of federal and state legislation. The United States Congress passed the School Access to Emergency Epinephrine Act in 2013 to provide an incentive to states to boost the stockpile of epinephrine at schools. A number of states, including California, passed laws requiring public schools to have epinephrine. In 2010, the United States Food and Drug Administration (FDA) changed its recommendations so that two EpiPen devices be sold in a package instead of one and that they be prescribed for at-risk patients, not just those with confirmed allergies; and
WHEREAS, The rising cost of EpiPen has implications for taxpayers. Over half of Californias children are insured through Medi-Cal, therefore the taxpayers are paying a large share of the cost of this medication; and
WHEREAS, Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor; and
WHEREAS, Patients who have to pay retail prices are being forced to buy EpiPen abroad, where it is cheaper, and are resorting to other devices that deliver epinephrine, including do-it-yourself syringes; and
WHEREAS, Even some ambulance providers in California have stopped the use of EpiPen to treat allergic shock and instead are drawing from a vial and injecting epinephrine by syringe. First responders in Seattle have developed such a kit and have sold them to public health agencies in five other states. There is a demonstration project in New York called Check and Inject New York that trains first responders to use syringe epinephrine kits in place of EpiPen to save money; and
WHEREAS, After recent widespread criticism, Mylan said it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers and employers pay. Those institutions will still face the brunt of the impact from the price hikes; and
WHEREAS, Offering co-payment assistance and free product to consumers is part of the standard playbook for manufacturers of expensive drugs. Efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medications ignores the fact that insurance companies bear the brunt of these unreasonable price increases, which results in higher premiums for all consumers; now, therefore, be it
Resolved by the Senate and the Assembly of the State of California, jointly, That the Legislature declares unnecessary and unexplained increases in pharmaceutical pricing is a harm to our health care system that will no longer be tolerated because the system cannot sustain it; and be it further
Resolved, That the Legislature urges the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to EpiPen; and be it further
Resolved, That the Legislature urges the Congress of the United States to investigate the impact that Mylans monopoly has had on the price hikes for EpiPen; and be it further
Resolved, That the Legislature urges the Congress and President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based only on what the market can bear rather than on providing a fair return on investment; and be it further
Resolved, That the Secretary of the Senate transmit copies of this resolution to the President and Vice President of the United States, to the Speaker of the House of Representatives, to the Majority Leader of the Senate, to each Senator and Representative from California in the Congress of the United States, to the Secretary of the United States Department of Health and Human Services, and to the Commissioner of Food and Drugs, and to the author for appropriate distribution.
|
Date
|
Status
|
|---|---|
| Aug 29, 2016 | Introduced. Referred to Com. on RLS. |
| Aug 30, 2016 | From committee: Ordered to third reading. |
| Aug 30, 2016 | In Assembly. Held at Desk. |
| Aug 30, 2016 | Read. Adopted. (Ayes 38. Noes 0.) Ordered to the Assembly. |
| Aug 30, 2016 | Read. Adopted. (Ayes 39. Noes 0. Page 5528.) Ordered to the Assembly. |
| Aug 31, 2016 | Assembly Rule 63 suspended. |
| Aug 31, 2016 | From committee: Be adopted. Ordered to third reading. (Ayes 14. Noes 0.) (August 31). |
| Aug 31, 2016 | In Senate. Ordered to engrossing and enrolling. |
| Aug 31, 2016 | Read. Adopted. Ordered to the Senate. |
| Aug 31, 2016 | Read. Adopted. (Ayes 60. Noes 0. Page 6546.) Ordered to the Senate. |
| Aug 31, 2016 | Referred to Com. on HEALTH. |
| Sep 9, 2016 | Chaptered by Secretary of State. Res. Chapter 191, Statutes of 2016. |
| Sep 9, 2016 | Enrolled and filed with the Secretary of State at 11 a.m. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 31, 2016 | SJR 29 Hernandez Senate Third Reading By CHIU | Assembly Floor |
Passed |
|
| Aug 31, 2016 | Be adopted. To third reading. | Assembly Standing Committee on Health |
Passed |
|
| Aug 30, 2016 | Senate 3rd Reading (Supplemental File 2) SJR29 Hernandez | Senate Floor |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
(Without Reference to File)
SENATE THIRD READING
STR Bill Id:SJR 29
Author:(Hernandez)
As Introduced Ver:August 29, 2016
Majority vote
SENATE VOTE: 39-0
Committee | Votes | Ayes | Noes |
Health | 14-0 | Wood, Bonilla, Burke, Campos, Chiu, Gomez, Lackey, Nazarian, Rodriguez, Santiago, Steinorth, Thurmond, Waldron, Gordon |
SUMMARY: Urges the Congress of the United States to investigate the impact that Mylan's monopoly has had on the price hikes for EpiPen, and urges the Congress and President to take action to limit the unrestrained ability of drug manufacturers to increase prices based only on what the market can bear rather than on providing a fair return on investment. Specifically, this resolution:
- Finds that millions benefit from life-saving drugs and devices, including Americans with allergies that can be treated by epinephrine, and last year doctors wrote 3.6 million prescriptions for EpiPen, which stops allergic reactions by quickly and safely injecting epinephrine.
- Finds that in 2007 Mylan NV purchased the rights to EpiPen and immediately began raising its price, and that in 2008 and 2009, Mylan raised the price by 5% and at the end of 2009 by another 19%, and from the fourth quarter of 2013 to the second quarter of 2016, Mylan raised EpiPen prices 15% every other quarter.
- Finds that a pack of two EpiPen devices now has a list price of over $600, an increase of 548% since Mylan began selling the drug according to Truven Health Analytics.
- Finds that the formula of EpiPen did not change, and it is no more effective in protecting against allergic reactions in 2016 than it was in 2007 and that during the same time, Mylan began an aggressive marketing and lobbying effort to increase demand for EpiPen, which included the passage of federal and state legislation.
- Finds that the rising cost of EpiPen has implications for taxpayers because over half of California's children are insured through Medi-Cal, therefore taxpayers are paying a large share of the cost of this medication.
- Finds that Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor and that patients who have to pay retail prices are being forced to buy EpiPen abroad, where it is cheaper, and are resorting to other devices that deliver epinephrine, including do-it-yourself syringes.
- Finds that after recent widespread criticism, Mylan said it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers and employers pay and those institutions will still face the brunt of the impact from the price hikes.
- Finds that offering co-payment assistance and free product to consumers is part of the standard playbook for manufacturers of expensive drugs and that efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medications ignores the fact that insurance companies bear the brunt of these unreasonable price increases, which results in higher premiums for all consumers.
- Resolves that the Legislature declares unnecessary and unexplained increases in pharmaceutical pricing is a harm to our health care system that will no longer be tolerated because the system cannot sustain it and that the Legislature urges the United States Food and Drug Administration (FDA) to reconsider its denial of approval for generic alternatives to EpiPen.
FISCAL EFFECT: None.
COMMENTS: According to the author, during the same time that Mylan was steadily increasing the price of EpiPens to reach over 500% of its list price in 2007, the company began a marketing and lobbying effort to increase demand for this product, which included the passage of federal and state legislation. The author states that in 2010, the FDA changed its recommendations so that two EpiPens be sold in a package instead of one and that they be prescribed for at-risk patients, not just those with allergies. The author notes that in 2013, Congress passed the School Access to Emergency Epinephrine Act to provide an incentive to states to boost the supply of epinephrine at schools. Following this, a number of states, including California, passed laws requiring public schools to have epinephrine. The author contends that Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor. Furthermore, in California, over half of our children are insured through Medi-Cal, therefore the public ends up paying a large share of the cost of the drug. The author also notes that after recent widespread criticism, Mylan announced that it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers, employers, emergency responders, and schools pay. Those institutions will still face the brunt of the impact from the price hikes and offering co-payment assistance and free product to consumers is part of the standard playbook for drug companies. The author states that efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medication ignores the fact that insurance companies bear the brunt of these unreasonable price increases and results in higher premiums for all consumers. The drug maker Mylan is taking advantage of its monopoly and exploiting a life-saving medication that countless families across California and the nation rely on and something must be done now to correct the market for this particular drug. The author concludes that the federal Administration and Congress have the power to limit the unrestrained ability of Mylan to gouge our health care system, and they should use it.
- Anaphylaxis. According to the National Institutes of Health, anaphylaxis is a severe, whole-body allergic reaction to a chemical that has become an allergen. After being exposed to a substance, such as bee sting venom, the person's immune system becomes sensitized to it. When the person is exposed to that allergen again, an allergic reaction may occur. Anaphylaxis happens quickly after the exposure, is severe, and involves the whole body. Tissues in different parts of the body release histamine and other substances. This causes the airways to tighten and leads to other symptoms. Some drugs (such as morphine, x-ray dye, and aspirin) may cause an anaphylactic-like reaction when people are first exposed to them. These reactions are not the same as the immune system response that occurs with true anaphylaxis. However, the symptoms, risk for complications, and treatment are the same for both types of reactions. Risks include a history of any type of allergic reaction.
- Epinephrine auto-injectors (EAI). An EAI is a medical device used to deliver a measured dose of epinephrine using auto-injector technology, most frequently for the treatment of acute allergic reactions to avoid or treat the onset of anaphylaxis. According to the Food Allergy Research and Education Web site, epinephrine is a highly effective medication that can reverse severe symptoms of anaphylaxis but must be administered promptly to be most effective. EpiPen and EpiPen Jr. (the version for smaller children) are commonly used EAIs. According to Mylan, which makes the two products, EpiPen contains 0.3mg of epinephrine and is intended for those who weigh 66 pounds or more, while EpiPen Jr. contains 0.15mg and is intended for patients weighing between 33 to 66 pounds. Mylan's product information states that it is not known if EpiPen and EpiPen Jr. are safe and effective in children who weigh less than 33 pounds. The devices are intended to be injected into the middle of the outer thigh, and patients are directed not to inject the device into a vein, buttock, fingers, toes, hands, or feet.
- EpiPens and generic alternatives. Epinephrine on its own is extremely cheap, just a few cents per dose. The auto-injecting device is the product that is protected under patent in this case. Mylan "owns" the EpiPen auto-injector device design, so competitors must find work-arounds in their devices to deliver the epinephrine into the patient's body. This task has proven to be difficult for EpiPen competitors. In 2015, Sanofi US issued a voluntary nationwide recall of its Auvi-Q due to potential inaccurate dosage delivery. In 2016, the FDA rejected Teva Pharmaceutical's generic epinephrine injector because it had reliability issues and therefore wasn't medically equivalent. Another company, Twinject, also discontinued their injectors in 2012. A generic product called Adrenaclick is on the market, but is not very popular and is not always covered by insurers.
- The Rising Costs of Drugs. According to the Centers for Medicare and Medicaid Services (CMS), prescription drug spending increased 12.2% to $297.7 billion in 2014, faster than the 2.4% growth in 2013. A study published in Health Affairs in December 2015 found that drug spending is growing faster than other health care spending in the United States (U.S.) – increasing 12.2% between 2013 and 2014. A Kaiser Family Foundation (KFF) analysis of data from the CMS and Truven Health Analytics shows that while drugs account for 10% of U.S. health spending, it represents 19% of the cost of employer insurance benefits. Some speculate that this disparity exists because the $3 trillion in U.S. health spending is a broad catchall which includes hospital care, physician services, drugs, research, administrative costs, public health activities, and long-term care. Additionally, some of the people served by Medicare and Medicaid (whose spending is counted in the national totals) require many services not typically used by those covered by employer health plans. According to an analysis by the chief executive officer (CEO) of the KFF, even that 19% figure is understated because while it includes prescriptions that patients fill at pharmacies, it does not include many of the expensive drugs administered in physicians' offices or hospitals. In Medicare, for example, retail prescription drugs represent 13% of overall spending while drugs administered mainly by physicians add an additional 6%.
According to the June 2016 California HealthCare Foundation's (CHCF) Issue Brief, in 2015, the total U.S. expenditure on prescription medicines was $425 billion, a 12.2% increase over 2014 total expenditure or an 8.5% increase when adjusted for net expenditures. CHCF states that U.S. pharmaceutical prices are among the highest worldwide, and escalating costs have been a concern for many years, presenting challenges for federal, state, and private purchasers.
- Drug pricing. Federal regulations prohibit the U.S. government from setting the price of pharmaceuticals, and patents on drugs, in effect, prohibiting competition, at least initially. Countries without these restrictions generally buy drugs for a fraction of the U.S. price. Pharmaceutical companies argue that high drug prices are justified because of the enormous cost and risk associated with bringing a drug to market and that payment for current drugs fund future innovation. Developing a new drug costs an average of $1.2 billion and takes 10 to 15 years. When a new drug provides a cure for a disease, as opposed to only treating symptoms, drug companies claim that a high upfront cost is mitigated by not having to treat symptoms indefinitely. However, critics point to numerous examples of drug companies charging high prices for drugs with only marginal improvements over cheaper alternatives, or astounding increases in pricing for drugs that have been on the market for years.
- Recent press. Over the last several days there have been numerous articles reporting on the rapidly rising costs of EpiPen. According to the Los Angeles Times the price has risen more than 500% from $94 when EpiPen was acquired by Mylan in 2007 to its current price of $608. On Thursday, August 25, 2016, Mylan began offering more financial aid to patients getting EpiPens, such as coupons to cover up to $300 off patient copayments, and on Monday, August 29, 2016, the company announced it will begin selling a generic version for $300 in the next several weeks.
On the same day, the heads of the House Committee on Oversight and Government Reform wrote to Mylan Chief Executive Heather Bresch, requesting information regarding how much Mylan receives from federal healthcare programs, information about its profits, as well as lobbying disclosure forms. Last week leaders of the Senate Judiciary Committee and the Senate Special Committee on Aging sent similar letters.
Analysis Prepared by: Lara Flynn / HEALTH / (916) 319-2097 FN: 0005023
Date of Hearing: August 31, 2016
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
SBPCA Bill Id:SJR 29
Author:(Hernandez) – As Introduced Ver:August 29, 2016
SENATE VOTE:
SUBJECT: EpiPen: pricing.
SUMMARY: Urges the Congress of the United States to investigate the impact that Mylan's monopoly has had on the price hikes for EpiPen, and urges the Congress and President to take action to limit the unrestrained ability of drug manufacturers to increase prices based only on what the market can bear rather than on providing a fair return on investment. Specifically, this resolution:
- Finds that millions benefit from life-saving drugs and devices, including Americans with allergies that can be treated by epinephrine, and last year doctors wrote 3.6 million prescriptions for EpiPen, which stops allergic reactions by quickly and safely injecting epinephrine.
- Finds that in 2007 Mylan NV purchased the rights to EpiPen and immediately began raising its price, and that in 2008 and 2009, Mylan raised the price by 5% and at the end of 2009 by another 19%, and from the fourth quarter of 2013 to the second quarter of 2016, Mylan raised EpiPen prices 15% every other quarter.
- Finds that a pack of two EpiPen devices now has a list price of over $600, an increase of 548% since Mylan began selling the drug according to Truven Health Analytics.
- Finds that the formula of EpiPen did not change, and it is no more effective in protecting against allergic reactions in 2016 than it was in 2007 and that during the same time, Mylan began an aggressive marketing and lobbying effort to increase demand for EpiPen, which included the passage of federal and state legislation.
- Finds that the rising cost of EpiPen has implications for taxpayers because over half of California's children are insured through Medi-Cal, therefore taxpayers are paying a large share of the cost of this medication.
- Finds that Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor and that patients who have to pay retail prices are being forced to buy EpiPen abroad, where it is cheaper, and are resorting to other devices that deliver epinephrine, including do-it-yourself syringes.
- Finds that after recent widespread criticism, Mylan said it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers and employers pay and those institutions will still face the brunt of the impact from the price hikes.
- Finds that offering co-payment assistance and free product to consumers is part of the standard playbook for manufacturers of expensive drugs and that efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medications ignores the fact that insurance companies bear the brunt of these unreasonable price increases, which results in higher premiums for all consumers.
- Resolves that the Legislature declares unnecessary and unexplained increases in pharmaceutical pricing is a harm to our health care system that will no longer be tolerated because the system cannot sustain it and that the Legislature urges the United States Food and Drug Administration (FDA) to reconsider its denial of approval for generic alternatives to EpiPen.
EXISTING LAW:
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which low income individuals are eligible for health care coverage.
- Requires drug manufacturers, under federal law, to obtain approval of new drugs from the FDA.
- Establishes the Sherman Law, administered by Department of Public Health (DPH), which, among other provisions, regulates the packaging, labeling, and advertising of drugs and medical devices in California.
- Prohibits, in the Sherman Law, the sale, delivery, or giving away of any new drug or new device unless it is either:
- A new drug, and a new drug application has been approved for it by the FDA, pursuant to federal law, or it is a new device for which a premarket approval application has been approved, and that approval has not been withdrawn, terminated, or suspended under the FDA; or,
- A new drug or new device for which DPH has approved a new drug or device application, and has not withdrawn, terminated, or suspended that approval.
- Requires DPH to adopt regulations to establish the application form and set the fee for licensure and renewal of a drug or device license.
FISCAL EFFECT: None.
COMMENTS:
- PURPOSE OF THIS RESOLUTION. According to the author, during the same time that Mylan was steadily increasing the price of EpiPens to reach over 500% of its list price in 2007, the company began a marketing and lobbying effort to increase demand for this product, which included the passage of federal and state legislation. The author states that in 2010, the FDA changed its recommendations so that two EpiPens be sold in a package instead of one and that they be prescribed for at-risk patients, not just those with allergies. The author notes that in 2013, Congress passed the School Access to Emergency Epinephrine Act to provide an incentive to states to boost the supply of epinephrine at schools. Following this, a number of states, including California, passed laws requiring public schools to have epinephrine. The author contends that Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor. Furthermore, in California, over half of our children are insured through Medi-Cal, therefore the public ends up paying a large share of the cost of the drug. The author also notes that after recent widespread criticism, Mylan announced that it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers, employers, emergency responders, and schools pay. Those institutions will still face the brunt of the impact from the price hikes and offering co-payment assistance and free product to consumers is part of the standard playbook for drug companies. The author states that efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medication ignores the fact that insurance companies bear the brunt of these unreasonable price increases and results in higher premiums for all consumers. The drug maker Mylan is taking advantage of its monopoly and exploiting a life-saving medication that countless families across California and the nation rely on and something must be done now to correct the market for this particular drug. The author concludes that the federal Administration and Congress have the power to limit the unrestrained ability of Mylan to gouge our health care system, and they should use it.
- BACKGROUND.
- Anaphylaxis. According to the National Institutes of Health, anaphylaxis is a severe, whole-body allergic reaction to a chemical that has become an allergen. After being exposed to a substance, such as bee sting venom, the person's immune system becomes sensitized to it. When the person is exposed to that allergen again, an allergic reaction may occur. Anaphylaxis happens quickly after the exposure, is severe, and involves the whole body. Tissues in different parts of the body release histamine and other substances. This causes the airways to tighten and leads to other symptoms. Some drugs (such as morphine, x-ray dye, and aspirin) may cause an anaphylactic-like reaction when people are first exposed to them. These reactions are not the same as the immune system response that occurs with true anaphylaxis. However, the symptoms, risk for complications, and treatment are the same for both types of reactions. Risks include a history of any type of allergic reaction.
- Epinephrine auto-injectors (EAI) An EAI is a medical device used to deliver a measured dose of epinephrine using auto-injector technology, most frequently for the treatment of acute allergic reactions to avoid or treat the onset of anaphylaxis. According to the Food Allergy Research and Education Website, epinephrine is a highly effective medication that can reverse severe symptoms of anaphylaxis but must be administered promptly to be most effective. EpiPen and EpiPen Jr. (the version for smaller children) are commonly used EAIs. According to Mylan, which makes the two products, EpiPen contains 0.3mg of epinephrine and is intended for those who weigh 66 pounds or more, while EpiPen Jr. contains 0.15mg and is intended for patients weighing between 33 to 66 pounds. Mylan’s product information states that it is not known if EpiPen and EpiPen Jr. are safe and effective in children who weigh less than 33 pounds. The devices are intended to be injected into the middle of the outer thigh, and patients are directed not to inject the device into a vein, buttock, fingers, toes, hands, or feet.
- EpiPens and generic alternatives. Epinephrine on its own is extremely cheap, just a few cents per dose. The auto-injecting device is the product that is protected under patent in this case. Mylan “owns” the EpiPen auto-injector device design, so competitors must find work-arounds in their devices to deliver the epinephrine into the patient’s body. This task has proven to be difficult for EpiPen competitors. In 2015, Sanofi US issued a voluntary nationwide recall of its Auvi-Q due to potential inaccurate dosage delivery. In 2016, the FDA rejected Teva Pharmaceutical’s generic epinephrine injector because it had reliability issues and therefore wasn't medically equivalent. Another company, Twinject, also discontinued their injectors in 2012. A generic product called Adrenaclick is on the market, but is not very popular and is not always covered by insurers.
- The rising costs of drugs. According to the Centers for Medicare and Medicaid Services (CMS), prescription drug spending increased 12.2% to $297.7 billion in 2014, faster than the 2.4% growth in 2013. A study published in Health Affairs in December 2015 found that drug spending is growing faster than other health care spending in the U.S. – increasing 12.2% between 2013 and 2014. A Kaiser Family Foundation (KFF) analysis of data from the CMS and Truven Health Analytics shows that while drugs account for 10% of U.S. health spending, it represents 19% of the cost of employer insurance benefits. Some speculate that this disparity exists because the $3 trillion in U.S. health spending is a broad catchall which includes hospital care, physician services, drugs, research, administrative costs, public health activities, and long-term care. Additionally, some of the people served by Medicare and Medicaid (whose spending is counted in the national totals) require many services not typically used by those covered by employer health plans. According to an analysis by the CEO of the KFF, even that 19% figure is understated because while it includes prescriptions that patients fill at pharmacies, it does not include many of the expensive drugs administered in physicians’ offices or hospitals. In Medicare, for example, retail prescription drugs represent 13% of overall spending while drugs administered mainly by physicians add an additional 6%.
According to the June 2016 California HealthCare Foundation’s (CHCF) Issue Brief, in 2015, the total U.S. expenditure on prescription medicines was $425 billion, a 12.2% increase over 2014 total expenditure or an 8.5% increase when adjusted for net expenditures. CHCF states that U.S. pharmaceutical prices are among the highest worldwide, and escalating costs have been a concern for many years, presenting challenges for federal, state, and private purchasers.
- Drug pricing. Federal regulations prohibit the U.S. government from setting the price of pharmaceuticals, and patents on drugs, in effect, prohibiting competition, at least initially. Countries without these restrictions generally buy drugs for a fraction of the U.S. price. Pharmaceutical companies argue that high drug prices are justified because of the enormous cost and risk associated with bringing a drug to market and that payment for current drugs fund future innovation. Developing a new drug costs an average of $1.2 billion and takes 10 to 15 years. When a new drug provides a cure for a disease, as opposed to only treating symptoms, drug companies claim that a high upfront cost is mitigated by not having to treat symptoms indefinitely. However, critics point to numerous examples of drug companies charging high prices for drugs with only marginal improvements over cheaper alternatives, or astounding increases in pricing for drugs that have been on the market for years.
- Recent press. Over the last several days there have been numerous articles reporting on the rapidly rising costs of EpiPen. According to the Los Angeles Times the price has risen more than 500% from $94 when EpiPen was acquired by Mylan in 2007 to its current price of $608. On Thursday, August 25, 2016, Mylan began offering more financial aid to patients getting EpiPens, such as coupons to cover up to $300 off patient copayments, and on Monday, August 29, 2016, the company announced it will begin selling a generic version for $300 in the next several weeks.
On the same day, the heads of the House Committee on Oversight and Government Reform wrote to Mylan Chief Executive Heather Bresch, requesting information regarding how much Mylan receives from federal healthcare programs, information about its profits, as well as lobbying disclosure forms. Last week leaders of the Senate Judiciary Committee and the Senate Special Committee on Aging sent similar letters.
- SUPPORT. The State Employees International Union (SEIU California) supports this resolution stating that for families struggling to afford this life-saving medicine, these outrageous price hikes are nothing short of devastating and limit access where it is most needed. SEIU California notes that the federal government is largely responsible for regulating drugs and devices such as the EpiPen, therefore this resolution which calls on the federal government to: reconsider its denial of approval for a generic alternative to the EpiPen; investigate the impact of Mylan's monopoly on price hikes; and, take action to limit the "unrestrained ability" of drug manufacturers to increase prices based only on what the market will bear rather than on a fair return on investment.
The California Labor Federation (CLF) supports this resolution, noting that the EpiPen is not an innovative new product—it has been in use since 1977 and research and development costs have been made back already. In 2007, Mylan bought the EpiPen, and raised the price steadily since then. CLF also points out that from 2007-2015, the CEO of Mylan’s total compensation went up 671%, at the same time that they were gouging families by raising the average wholesale price of the EpiPen 461%. Mylan is also a tax dodger, having completed a tax inversion and reincorporating in the Netherlands in 2014 to avoid paying tax in the United States. CLF concludes that Mylan’s outrageous price increases are not an isolated incident. Pharmaceutical companies raise the prices of drugs to treat asthma, diabetes, high-blood pressure, and many other conditions, multiple times a year, burdening patients, employers, taxpayers, and our health care system.
Kaiser Permanente (KP) and the California Association of Health Plans (CAHP) support this resolution, writing that it is particularly meaningful because it calls attention to the overall dysfunction of the pharmaceutical marketplace resulting from decades of federal law and regulatory processes that have stymied any real competition among drug manufacturers. KP and CAHP note that while the behavior of Mylan is front and center this month, sadly they are not an outlier. Pharmaceutical companies regularly increase the price of their product, annually or sometimes twice a year. KP and CAHP state these year-over-year "small" increases of 9-15% lead to dramatic, cumulative cost impacts that threaten the affordability of health care. - RELATED LEGISLATION.
- AB 1386 (Low) permits a health care provider to issue a prescription for, and a pharmacy to dispense, an epinephrine auto-injector to an authorized entity, which is defined as any entity or organization that employs at least one person that has completed an approved training course on the emergency use of epinephrine auto-injectors; revises the definition of “epinephrine auto-injector” to eliminate the reference to a spring-activated needle, and instead define this term as a “disposable delivery device designed for automatic injection of a premeasured dose of epinephrine into the human body to prevent or treat a life-threatening allergic reaction. AB 1386 has been passed by the Legislature, and is pending action by the Governor.
- SB 1010 (Hernandez) requires health care service plans (health plans) and health insurers that report rate information to also include information regarding covered prescription drugs, as specified. Requires the Department of Managed Health Care and the California Department of Insurance to compile and report this data in an aggregated report to demonstrate the overall impact of drug costs on health care premiums. Requires any manufacturer of a prescription drug, who sells to or is reimbursed by a state purchaser, health plan, health insurer, or pharmacy benefit manager, to provide notice describing a price increase, as specified. SB 1010 is on the Assembly Inactive File.
- AB 1386 (Low) permits a health care provider to issue a prescription for, and a pharmacy to dispense, an epinephrine auto-injector to an authorized entity, which is defined as any entity or organization that employs at least one person that has completed an approved training course on the emergency use of epinephrine auto-injectors; revises the definition of “epinephrine auto-injector” to eliminate the reference to a spring-activated needle, and instead define this term as a “disposable delivery device designed for automatic injection of a premeasured dose of epinephrine into the human body to prevent or treat a life-threatening allergic reaction. AB 1386 has been passed by the Legislature, and is pending action by the Governor.
- PREVIOUS LEGISLATION.
- AB 463 (Chiu) of 2015 would have established the Pharmaceutical Cost Transparency Act of 2016, which requires that a pharmaceutical manufacturer that sells a prescription drug in California file a report with OSHPD if the wholesale acquisition cost of the drug is more than $10,000 annually or per course of treatment. AB 463 died in the Assembly Health Committee.
- SB 1266 (Huff), Chapter 321, Statutes of 2014, requires school districts, county offices of education, and charter schools to provide emergency epinephrine auto-injectors to school nurses or trained personnel who have volunteered, as specified. Authorizes school nurses or trained personnel to use the epinephrine auto-injectors to provide emergency medical aid to persons suffering, or reasonably believed to be suffering, from an anaphylactic reaction.
REGISTERED SUPPORT / OPPOSITION:
Support
AFSCME
Amalgamated Transit Union
Anthem
Association of California Life and Health Insurance Companies
Blue Shield of California
California Association of Health Plans
California Labor Federation
California Professional Firefighters
California School Employees Association
California Teamsters Public Affairs Council
Cigna
Health Access California
International Association of Machinists and Aerospace Workers
International Longshore and Warehouse Union
Jockeys Guild
Kaiser Permanente
Professional & Technical Engineers, Local 21, AFL-CIO
SAG-AFTRA
SEIU California
United Nurses Association of California
UNITE HERE
Utility Workers Union of America
Opposition
None on file.
Analysis Prepared by: Lara Flynn / HEALTH / (916) 319-2097
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SJR 29 |
THIRD READING
Bill No: SJR 29
Introduced: 8/29/16
This resolution makes various legislative findings related to the increase in the price of the EpiPen by the pharmaceutical manufacturer Mylan, urges the federal Food and Drug Administration to reconsider its denial of generic alternatives to EpiPen, and urges Congress to investigate the impact that Mylan’s monopoly has had on the price hikes for EpiPen and to take action to limit the unrestrained ability of drug manufacturers to increase prices based only on what the market will bear.
ANALYSIS: Existing law requires school districts, county offices of education (COE), and charter schools to provide emergency epinephrine auto-injectors (EAIs) to school nurses or trained personnel who have volunteered, as specified. Additionally, it authorizes school nurses or trained personnel to use the EAIs to provide emergency medical aid to persons suffering, or reasonably believed to be suffering, from an anaphylactic reaction.
This resolution:
- Makes the following legislative findings:
- Millions benefit from life-saving drugs and devices, including Americans with allergies that can be treated by epinephrine;
- Last year, doctors wrote 3.6 million prescriptions for EpiPen, which stops allergic reactions by quickly and safely injecting epinephrine;
- In 2007 Mylan NV purchased the rights to EpiPen and immediately began raising its price. In 2008 and 2009, Mylan raised the price by 5%, and at the end of 2009 it raised the price by another 19%. From 2010 to 2013, Mylan imposed a series of 10% price hikes. And from the fourth quarter of 2013 to the second quarter of 2016, Mylan raised EpiPen prices 15% every other quarter;
- A pack of two EpiPen devices now has a list price of over $600, an increase of 548% since Mylan began selling the drug, according to Truven Health Analytics;
- The formula of EpiPen did not change, and it is no more effective in protecting against allergic reactions in 2016 than it was in 2007;
- During the same time, Mylan began an aggressive marketing and lobbying effort to increase demand for EpiPen, which included the passage of federal and state legislation. The United States Congress passed the School Access to Emergency Epinephrine Act in 2013 to provide an incentive to states to boost the stockpile of epinephrine at schools. A number of states, including California, passed laws requiring public schools to have epinephrine. In 2010, the United States Food and Drug Administration (FDA) changed its recommendations so that two EpiPen devices be sold in a package instead of one and that they be prescribed for at-risk patients, not just those with confirmed allergies;
- The rising cost of EpiPen has implications for taxpayers. Over half of California’s children are insured through Medi-Cal, therefore the taxpayers are paying a large share of the cost of this medication;
- Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor;
- Patients who have to pay retail prices are being forced to buy EpiPen abroad, where it is cheaper, and are resorting to other devices that deliver epinephrine, including do-it-yourself syringes;
- Even some ambulance providers in California have stopped the use of EpiPen to treat allergic shock and instead are drawing from a vial and injecting epinephrine by syringe. First responders in Seattle have developed such a kit and have sold them to public health agencies in five other states. There is a demonstration project in New York called “Check and Inject New York” that trains first responders to use syringe epinephrine kits in place of EpiPen to save money;
- After recent widespread criticism, Mylan said it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers and employers pay. Those institutions will still face the brunt of the impact from the price hikes; and,
- Offering co-payment assistance and free product to consumers is part of the standard playbook for manufacturers of expensive drugs. Efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medications ignores the fact that insurance companies bear the brunt of these unreasonable price increases, which results in higher premiums for all consumers.
- Declares that unnecessary and unexplained increases in pharmaceutical pricing is a harm to our health care system that will no longer be tolerated because the system cannot sustain it.
- Urges:
- The FDA to reconsider its denial of approval for generic alternatives to EpiPen;
- The Congress of the United States to investigate the impact that Mylan’s monopoly has had on the price hikes for EpiPen; and,
- The Congress and President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based only on what the market can bear rather than on providing a fair return on investment.
Comments
Author’s statement. During the same time that Mylan was steadily increasing the price of EpiPens to reach over 500% of its list price in 2007, the company began a marketing and lobbying effort to increase demand for this product, which included the passage of federal and state legislation. In 2010, the FDA changed its recommendations so that two EpiPens be sold in a package instead of one and that they be prescribed for at-risk patients, not just those with allergies. In 2013, Congress passed the School Access to Emergency Epinephrine Act to provide an incentive to states to boost the supply of epinephrine at schools. Following this, a number of states, including California, passed laws requiring public schools to have epinephrine. Mylan has an effective monopoly that it is using to maximize profit because there is no equivalent generic competitor. In California, over half of our children are insured through Medi-Cal, therefore the public ends up paying a large share of the cost of the drug. After recent widespread criticism, Mylan announced that it would expand access and increase benefits to programs that it uses to help consumers pay less, but those changes do not alter the prices that insurers, employers, emergency responders, and schools pay. Those institutions will still face the brunt of the impact from the price hikes. Offering co-payment assistance and free product to consumers is part of the standard playbook for drug companies. Efforts by drug makers to shield consumers from the out-of-pocket costs associated with the rapidly increasing cost of their medication ignores the fact that insurance companies bear the brunt of these unreasonable price increases and results in higher premiums for all consumers. The drug maker Mylan is taking advantage of its monopoly and exploiting a life-saving medication that countless families across California and the nation rely on. Something must be done now to correct the market for this particular drug. The federal Administration and Congress have the power to limit the unrestrained ability of Mylan to gouge our health care system, and they should use it.
Anaphylaxis. According to the National Institutes of Health, anaphylaxis is a severe, whole-body allergic reaction to a chemical that has become an allergen. After being exposed to a substance, such as bee sting venom, the person's immune system becomes sensitized to it. When the person is exposed to that allergen again, an allergic reaction may occur. Anaphylaxis happens quickly after the exposure, is severe, and involves the whole body. Tissues in different parts of the body release histamine and other substances. This causes the airways to tighten and leads to other symptoms. Some drugs (such as morphine, x-ray dye, and aspirin) may cause an anaphylactic-like reaction when people are first exposed to them. These reactions are not the same as the immune system response that occurs with true anaphylaxis. However, the symptoms, risk for complications, and treatment are the same for both types of reactions. Risks include a history of any type of allergic reaction.
Epinephrine auto-injector. An EAI is a medical device used to deliver a measured dose of epinephrine using auto-injector technology, most frequently for the treatment of acute allergic reactions to avoid or treat the onset of anaphylaxis. According to the Food Allergy Research and Education Web site, epinephrine is a highly effective medication that can reverse severe symptoms of anaphylaxis but must be administered promptly to be most effective. EpiPen and EpiPen Jr. (the version for smaller children) are commonly used EAIs. According to Mylan, which makes the two products, EpiPen contains 0.3mg of epinephrine and is intended for those who weigh 66 pounds or more, while EpiPen Jr. contains 0.15mg and is intended for patients weighing between 33 to 66 pounds. Mylan’s product information states that it is not known if EpiPen and EpiPen Jr. are safe and effective in children who weigh less than 33 pounds. The devices are intended to be injected into the middle of the outer thigh, and patients are directed not to inject the device into a vein, buttock, fingers, toes, hands, or feet.
EpiPens and generic alternatives. Epinephrine on its own is extremely cheap, just a few cents per dose. The auto-injecting device is the product that is protected under patent in this case. Mylan “owns” the EpiPen auto-injector device design, so competitors must find work-arounds in their devices to deliver the epinephrine into the patient’s body. This task has proven to be difficult for EpiPen competitors. In 2015, Sanofi US issued a voluntary nationwide recall of its Auvi-Q due to potential inaccurate dosage delivery. In 2016, the FDA rejected Teva Pharmaceutical’s generic epinephrine injector because it had reliability issues and therefore wasn't medically equivalent. Another company, Twinject, also discontinued their injectors in 2012. A generic product called Adrenaclick is on the market, but is not very popular and is not always covered by insurers. On August 29, 2016, Mylan announced it would offer the first generic to the EpiPen for $300, a 50% discount from the brand price.
Congressional action. Several different letters from the United States Congress have been sent to the Chief Executive Officer of Mylan in the past two weeks, following the most recent increase to the price of EpiPen. These letters include one from the House of Representative’s Committee on Oversight and Government Reform, signed by the chair as well as the ranking member; a letter signed by 20 Democratic members of the U.S. Senate; and, a letter from Senator Charles Grassley, Chairman of the Committee on the Judiciary. The letter from the House Committee on Oversight and Government Reform requested a number of documents from Mylan, including documents relating to the company’s gross and net revenues from the sales of the EpiPen since its acquisition, documents relating to the company’s expenses from the manufacture and sale of the EpiPen, and any cost estimates, profit projections, or other anlayses relating to the company’s current and future sales of the EpiPen. Senator Grassley’s letter requested that Mylan explain the changes it has made to EpiPen since the acquisition that have caused it to increase the price, any analyses conducted by Mylan in determining the price of EpiPens, and Mylan’s advertising budget for the product. The letter signed by the Democratic members of the U.S. Senate requested answers to a number of questions, including the number of consumers who have used certain consumer savings assistance programs offered by Mylan, and how Mylan justifies charging $600 for the branded product when it claims that the new generic alternative it will offer at $300 will be identical to the brand name version.
Related/Prior Legislation
AB 1386 (Low, 2016) permits a health care provider to issue a prescription for, and a pharmacy to dispense, an EAI to an authorized entity, which is defined as any entity or organization that employs at least one person that has completed an approved training course on the emergency use of EAIs. Also, revises the definition of “epinephrine auto-injector” to eliminate the reference to a spring-activated needle, and instead defines this term as a “disposable delivery device designed for automatic injection of a premeasured dose of epinephrine into the human body to prevent or treat a life-threatening allergic reaction. AB 1386 has been passed by the Legislature, and is pending action by the Governor.
SB 1266 (Huff, Chapter 321, Statutes of 2014) required school districts, COE, and charter schools provide emergency EAIs to school nurses or trained personnel who have volunteered, as specified. Additionally, it authorized school nurses or trained personnel to use the EAIs to provide emergency medical aid to persons suffering, or reasonably believed to be suffering, from an anaphylactic reaction.
SB 669 (Huff, Chapter 725, Statutes of 2013) permitted a prehospital emergency medical care person or lay rescuer to obtain and use an EAI in emergency situations with certification of training, as specified.
SB 1069 (Pavley, Chapter 512, Statutes of 2010), in addition to expanding the scope of practice for physician assistants in other instances, added physician assistants, in addition to physician and surgeons, from whom a school pupil must obtain a written statement in order to carry and self-administer a prescription EAI.
SB 1912 (Ashburn, Chapter 846, Statutes of 2004) permitted pupils to carry and self-administer inhaled asthma medication or an EAI at school, as specified.
AB 559 (Wiggins, Chapter 458, Statutes of 2001) was identical to AB 1791 (see below).
AB 1791 (Wiggins, 2000) would have established provisions of law that permit a school district or COE to provide emergency EAIs to trained personnel, and permit trained personnel to utilize these EAIs to provide emergency medical aid to persons suffering from an anaphylactic reaction at a school or during a school activity. The bill was vetoed by Governor Davis who stated that the shortage of school nurses with the knowledge necessary to administer medications would assure that the bulk of school personnel administering epinephrine in emergencies would be lay personnel. The Governor further stated that lay persons cannot receive the necessary background in a limited training program that would provide the essential medical judgment skills required to administer medication in an emergency situation.
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
Amalgamated Transit Union California Professional Firefighters
American Federation of State, County and Municipal Employees
Anthem Blue Cross
Association of California Life and Health Insurance Companies
Blue Shield of California
California Association of Health Plans
California Labor Federation
California School Employees Association, AFL-CIO
California Teamsters Public Affairs Council
Cigna
Consumers Union
Health Access California
International Association of Machinists and Aerospace Workers
International Federation of Professional & Technical Engineers
International Longshore and Warehouse Union
Jockey’s Guild
Kaiser Permanente
Screen Actors Guild‐American Federation of Television and Radio Artists
Service Employees International Union California
UNITE HERE!
United Health Care Professionals
United Nurses Association of California
Utility Workers Union of America AFL-CIO
OPPOSITION: (Verified 8/30/16)
None received
Prepared by: Melanie Moreno / HEALTH /
8/30/16 16:45:06
**** END ****
Discussed in Hearing
View Older HearingsBill Author
Bill Co-Author(s):